AKUR8/AG2R-LA-MONDIALE
29.6.2021 09:02:08 CEST | Business Wire | Press release
AG2R LA MONDIALE and Akur8 are delighted to announce their collaboration to transform AG2R LA MONDIALE's health insurance pricing process. This move underlines AG2R LA MONDIALE's desire to encourage innovation for the benefit of its policyholders. It also reinforces Akur8's relevance in the health insurance sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005016/en/
Specifically developed for insurance companies, Akur8's solution enhances their pricing process by automating risk and demand modeling, using a proprietary technology powered by transparent artificial intelligence. Akur8 enables insurers to significantly reduce modeling times, speed up time-to-market and increase predictive power of their models, while retaining absolute transparency and control.
With Akur8, AG2R LA MONDIALE is challenging its health insurance products’ pricing approach in order to offer its policyholders fairer, more transparent and more tailored prices.
"We are delighted to be opening this new chapter with AG2R LA MONDIALE. This move underlines their innovative spirit and ability to adapt constantly in order to serve their clients better, while putting digital transformation at the heart of their plans," said Samuel Falmagne, CEO of Akur8.
"This collaboration with AG2R LA MONDIALE marks a significant step forward in Akur8's continuous development. It reinforces the solution's relevance for health insurance and consolidates our presence in France," said Brune de Linares, Chief of Sales at Akur8.
"We are delighted to collaborate with Akur8. We are constantly seeking to provide better support to our policyholders, in an environment that calls for ever more agility and adaptability. This experimentation with Akur8 is a prime example of this approach. We hope that this unique, intuitive and innovative solution will provide value in the key process of pricing," said Anne-Charlotte de Raigniac, Director of actuarial services and medical approvals at AG2R LA MONDIALE.
About AG2R LA MONDIALE:
As a specialist in social and patrimonial protection in France, AG2R LA MONDIALE insures individuals, businesses and professional branches, providing health protection, protecting assets and income, guarding against accidents and preparing for retirement. The Group has over 15 million policyholders and provides day-to-day support to 500,000 businesses. With more than 11,000 employees, AG2R LA MONDIALE has a presence throughout mainland France and beyond. As a partnership with joint, cooperative governance, the Group cultivates a unique social protection model that closely combines profitability and solidarity, performance and social commitment. Every year it spends millions of euros helping vulnerable people and supporting individual and collaborative initiatives.
Stay up to date: www.ag2rlamondiale.fr
/ @AG2RLAMONDIALE
About Akur8
Akur8 revolutionizes insurance pricing with transparent AI. Akur8 has developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control over the models created, as required by regulators worldwide. Akur8 is the only solution on the market that reconciles the Machine Learning and Actuarial worlds.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
